<DOC>
	<DOCNO>NCT00003351</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase II trial compare effectiveness two regimen irinotecan treat patient refractory metastatic breast cancer .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Refractory Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity toxicity two different schedule irinotecan treatment patient refractory metastatic breast cancer receive 1 2 previous chemotherapy regimen ( one prior therapy metastatic disease one adjuvant therapy ) . II . Compare time progression , survival , quality life patient 2 different schedule irinotecan . OUTLINE : This randomize study . Patients stratify accord dominant disease ( visceral vs nonvisceral ) , performance status ( 0-1 v 2 ) , prior chemotherapy metastatic setting ( yes v ) . Patients assign arm I receive irinotecan intravenously 90 minute every week 4 week follow 2 week rest period . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Patients assign arm II receive irinotecan intravenously 90 minute every 3 week 6 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Quality life assess treatment . Patients follow every 3 month 2 year , annually 1 year . PROJECTED ACCRUAL : A total 42-100 patient ( 21-50 patient per arm ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast progress locoregional metastatic disease Measurable evaluable indicator lesion No uncontrolled CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 0.3 mg/dL upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine great 1.0 mg/dL ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : No uncontrolled infection No chronic debilitate disease Not pregnant lactate Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since chemotherapy No 2 prior chemotherapy regimens metastatic disease No 1 prior chemotherapy regimen adjuvant set At least 1 prior regimen contain taxane doxorubicin metastatic disease adjuvant set Endocrine therapy : Not specify Radiotherapy : No radiotherapy great 25 % bone marrow No prior treatment strontium 89 Surgery : At least 4 week since major surgery Other : No concurrent metoclopramide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>